Tell us how we can help
Clinician-to-clinician guidance
Coding, billing and reimbursement questions
Finding my sales representative
Support with an order
Since 2012, the American Academy of Pediatrics has recommended human milk as the primary source of nutrition for preterm infants, with appropriate fortification for those born weighing <1.5 kg.1 Fortification with human milk–based fortifiers is the only way to ensure these medically fragile infants receive an exclusive human milk diet (EHMD).
Prolacta products used as a part of that Exclusive Human Milk Diet (EHMD),2 as compared to cow milk–based fortifiers, have been shown in clinical studies to benefit critically ill, premature infants in the Special Care Baby Unit (NICU) weighing ≤1250 g at birth in many ways including to:
First and only pharmaceutical-grade manufacturing facilities for the testing and processing of human milk
Exceed food-product industry requirements by following stringent quality and safety standards based on those for the human plasma and blood industry in the US
Our human milk laboratory and manufacturing processes are regulated by the US Food and Drug Administration (FDA).
All Prolacta nutritional products are pasteurised to ensure the highest quality and safety, using time and temperature profiles defined by the US Food and Drug Administration (FDA) in its Pasteurised Milk Ordinance (PMO) to destroy pathogenic viruses and bacteria.
While there are other pasteurisation and sterilisation processes used in the human milk banking industry, only products manufactured with our pasteurisation process are clinically shown to improve health and reduce complications when used as part of an exclusive human milk diet (EHMD) in the neonatal intensive care unit (NICU). There is no clinical data showing similar results using products processed by any other method.
Prolacta’s 100% human milk–based nutritional products contain a wide spectrum of human milk oligosaccharides (HMOs).13 The immunity, prebiotic and gut maturation benefits that human milk oligosaccharides (HMOs) promote may have a role in the health outcomes attributed to an Exclusive Human Milk Diet (EHMD), including Prolacta’s products.14
To learn more
For more than two decades, we have been advancing the science of human milk to improve the health of premature, critically ill infants worldwide.
Clinician-to-clinician guidance
Coding, billing and reimbursement questions
Finding my sales representative
Support with an order
*Estimated number of premature infants fed Prolacta’s products from January 2007 to December 2022; data on file.